Skip to main
PAVM
PAVM logo

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc., a commercial-stage medical technology company, demonstrated growth in its EsoGuard testing, processing 2,841 tests in Q3, reflecting an increase from previous quarters, indicating a strengthening demand for its diagnostics products. The company's current valuation is seen as attractive, balancing the high risks associated with its operations against substantial upside opportunities, particularly as its product lines continue to advance toward broader commercialization. Additionally, projections suggest significant growth potential for the company’s offerings in the upcoming years, particularly for its medical devices and digital health segments.

Bears say

PAVmed Inc has reported a pro forma net loss of $0.8 million, equating to an earnings per share (EPS) of $(0.05), which is significantly better than prior estimates but still indicates ongoing financial challenges. The company experienced a decline in the number of EsoGuard tests processed, which decreased to 2,756 in Q2 from 3,034 in Q1, reflecting a concerning downward trend in service utilization. Additionally, PAVmed faces numerous operational and market risks, including balance sheet and liquidity pressures, regulatory hurdles, and competition, all of which complicate its path to growth and commercialization.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.